We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Newly Developed Immunoassay Evaluated for Infectious Diseases

By LabMedica International staff writers
Posted on 23 Dec 2020
Print article
Image: The Alinity i is a compact, immunoassay system that can reliably be used to diagnose infectious diseases (Photo courtesy of Abbott Laboratories).
Image: The Alinity i is a compact, immunoassay system that can reliably be used to diagnose infectious diseases (Photo courtesy of Abbott Laboratories).
Although a diagnosis of infectious diseases is essential for timely treatment, the performance of diagnostic tests has been hardly evaluated due to variable results that are influenced by multiple factors in different conditions.

Immunoassays are bioanalytical methods to measure the concentration of an analyte through the reaction of an antigen and an antibody. Most diagnostic tests of infectious diseases are performed in a qualitative manner. By applying a cutoff or ordinal scale to the quantitative results, converted qualitative results reveal discontinuous and reduced information and the result near the cutoff shows high uncertainty.

Medical Laboratory Scientists at Seoul National University Hospital (Seoul, Korea) evaluated the precision, linearity, correlation, and carryover of the analytical performances for the Alinity i by comparison with ARCHITECT i2000SR system (Abbott Laboratories, Abbott Park, IL, USA). For evaluation of compatibility, a total of 800 samples were derived from healthy adults and patients with positive results for various infectious diseases from December 2018 to December 2019.

A total of 16 analytes were selected: HAV Ab IgG(signal/cutoff (S/CO)), HBsAg (S/CO), HBeAg (S/CO), anti‐HBc (S/CO), anti‐HBe (S/CO), anti‐HBs (mIU/mL), anti‐HCV (S/CO), HIV Ag/Ab (S/CO), EBV VCA IgM (S/CO), EBV VCA IgG (S/CO), EBV EBNA IgG (S/CO), CMV IgM (relative light units, RLU), CMV IgG (AU/mL), Toxoplasma IgG (IU/mL), Rubella IgG (IU/mL), and Syphilis TP (S/CO). Among them, anti‐HBs (mIU/mL), CMV IgG (AU/mL), Toxoplasma IgG (IU/mL), and Rubella IgG (IU/mL) are quantitative tests, and the remaining analytes are qualitative tests.

The team reported that for low, medium, and high level of four quantitative analytes (anti‐HBs, CMV IgG, Toxoplasma IgG, and Rubella IgG), the percent coefficient of variation (%CV) of repeatability and intermediate precision were between 0% and 4.18%. For four quantitative analytes (anti‐HBs, CMV IgG, Toxoplasma IgG, and Rubella IgG), all correlation coefficients (r2) for these analytes were ≥ 0.99, representing excellent linearity ranges. In the method comparison between the Alinity i and ARCHITECT i2000SR system, all quantitative analytes showed a very strong correlation (r ≥ 0.994) based on Deming regression. All carryover rate for quantitative and qualitative analytes were less than 1.0% (−0.11% ~ 0.21%).

The authors concluded that the Alinity i system characterized had an excellent performance by ensuring reliable measurements for clinical laboratories and would be suitable as a routine immunoassay analyzer for screening infectious diseases. The study was published on December 7, 2020 in the Journal of Clinical Laboratory Analysis.


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Troponin I Test
Quidel Triage Troponin I Test
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The study demonstrated that electric-field molecular fingerprinting can probe cancer (Photo courtesy of ACS Central Science, 2025, 10.1021/acscentsci.4c02164)

New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma

Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more

Molecular Diagnostics

view channel
Image: The test monitors blood levels of DNA fragments released by dying tumor cells (Photo courtesy of 123RF)

Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer

Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.